Literature DB >> 20736995

Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerström test for nicotine dependence.

Jennifer Wessel1, Sarah M McDonald, David A Hinds, Renee P Stokowski, Harold S Javitz, Michael Kennemer, Ruth Krasnow, William Dirks, Jill Hardin, Steven J Pitts, Martha Michel, Lisa Jack, Dennis G Ballinger, Jennifer B McClure, Gary E Swan, Andrew W Bergen.   

Abstract

Common single-nucleotide polymorphisms (SNPs) at nicotinic acetylcholine receptor (nAChR) subunit genes have previously been associated with measures of nicotine dependence. We investigated the contribution of common SNPs and rare single-nucleotide variants (SNVs) in nAChR genes to Fagerström test for nicotine dependence (FTND) scores in treatment-seeking smokers. Exons of 10 genes were resequenced with next-generation sequencing technology in 448 European-American participants of a smoking cessation trial, and CHRNB2 and CHRNA4 were resequenced by Sanger technology to improve sequence coverage. A total of 214 SNP/SNVs were identified, of which 19.2% were excluded from analyses because of reduced completion rate, 73.9% had minor allele frequencies <5%, and 48.1% were novel relative to dbSNP build 129. We tested associations of 173 SNP/SNVs with the FTND score using data obtained from 430 individuals (18 were excluded because of reduced completion rate) using linear regression for common, the cohort allelic sum test and the weighted sum statistic for rare, and the multivariate distance matrix regression method for both common and rare SNP/SNVs. Association testing with common SNPs with adjustment for correlated tests within each gene identified a significant association with two CHRNB2 SNPs, eg, the minor allele of rs2072660 increased the mean FTND score by 0.6 Units (P=0.01). We observed a significant evidence for association with the FTND score of common and rare SNP/SNVs at CHRNA5 and CHRNB2, and of rare SNVs at CHRNA4. Both common and/or rare SNP/SNVs from multiple nAChR subunit genes are associated with the FTND score in this sample of treatment-seeking smokers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736995      PMCID: PMC3055324          DOI: 10.1038/npp.2010.120

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  89 in total

1.  Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence.

Authors:  M A Silverman; M C Neale; P F Sullivan; C Harris-Kerr; B Wormley; H Sadek; Y Ma; K S Kendler; R E Straub
Journal:  Am J Med Genet       Date:  2000-10-09

2.  Sample size requirements for matched case-control studies of gene-environment interaction.

Authors:  W James Gauderman
Journal:  Stat Med       Date:  2002-01-15       Impact factor: 2.373

3.  Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2).

Authors:  Kira K Lueders; Stella Hu; Louise McHugh; Max V Myakishev; Leo A Sirota; Dean H Hamer
Journal:  Nicotine Tob Res       Date:  2002-02       Impact factor: 4.244

Review 4.  A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins.

Authors:  Ming D Li; Rong Cheng; Jennie Z Ma; Gary E Swan
Journal:  Addiction       Date:  2003-01       Impact factor: 6.526

5.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

6.  Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.

Authors:  B Buisson; D Bertrand
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

7.  Rare variants create synthetic genome-wide associations.

Authors:  Samuel P Dickson; Kai Wang; Ian Krantz; Hakon Hakonarson; David B Goldstein
Journal:  PLoS Biol       Date:  2010-01-26       Impact factor: 8.029

8.  Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation.

Authors:  Ju Wang; Ming D Li
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

Review 9.  Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction.

Authors:  Yann S Mineur; Marina R Picciotto
Journal:  Biochem Pharmacol       Date:  2007-06-14       Impact factor: 5.858

10.  Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.

Authors:  Gary E Swan; Tim McAfee; Susan J Curry; Lisa M Jack; Harold Javitz; Sara Dacey; Katherine Bergman
Journal:  Arch Intern Med       Date:  2003-10-27
View more
  40 in total

1.  Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence.

Authors:  Gabe Haller; Todd Druley; Francesco L Vallania; Robi D Mitra; Ping Li; Gustav Akk; Joe Henry Steinbach; Naomi Breslau; Eric Johnson; Dorothy Hatsukami; Jerry Stitzel; Laura J Bierut; Alison M Goate
Journal:  Hum Mol Genet       Date:  2011-10-31       Impact factor: 6.150

2.  Deep Sequencing of Three Loci Implicated in Large-Scale Genome-Wide Association Study Smoking Meta-Analyses.

Authors:  Shaunna L Clark; Joseph L McClay; Daniel E Adkins; Karolina A Aberg; Gaurav Kumar; Sri Nerella; Linying Xie; Ann L Collins; James J Crowley; Corey R Quakenbush; Christopher E Hillard; Guimin Gao; Andrey A Shabalin; Roseann E Peterson; William E Copeland; Judy L Silberg; Hermine Maes; Patrick F Sullivan; Elizabeth J Costello; Edwin J van den Oord
Journal:  Nicotine Tob Res       Date:  2015-08-17       Impact factor: 4.244

Review 3.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

4.  Identification of CHRNA5 rare variants in African-American heavy smokers.

Authors:  Glenn A Doyle; Andrew D Chou; Wint Thu Saung; Alison T Lai; Falk W Lohoff; Wade H Berrettini
Journal:  Psychiatr Genet       Date:  2014-06       Impact factor: 2.458

Review 5.  Introduction to deep sequencing and its application to drug addiction research with a focus on rare variants.

Authors:  Shaolin Wang; Zhongli Yang; Jennie Z Ma; Thomas J Payne; Ming D Li
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

6.  New associations of the genetic polymorphisms in nicotinic receptor genes with the risk of lung cancer.

Authors:  Anna Chikova; Hans-Ulrich Bernard; Igor B Shchepotin; Sergei A Grando
Journal:  Life Sci       Date:  2012-01-17       Impact factor: 5.037

7.  Testing genetic association with rare variants in admixed populations.

Authors:  Xianyun Mao; Yun Li; Yichuan Liu; Leslie Lange; Mingyao Li
Journal:  Genet Epidemiol       Date:  2012-10-02       Impact factor: 2.135

8.  Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.

Authors:  Toni-Kim Clarke; Richard C Crist; Kyle M Kampman; Charles A Dackis; Helen M Pettinati; Charles P O'Brien; David W Oslin; Thomas N Ferraro; Falk W Lohoff; Wade H Berrettini
Journal:  Neurosci Lett       Date:  2013-02-20       Impact factor: 3.046

9.  Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.

Authors:  Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

10.  A signal peptide missense mutation associated with nicotine dependence alters α2*-nicotinic acetylcholine receptor function.

Authors:  Bhagirathi Dash; Ronald J Lukas; Ming D Li
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.